TAVR Talks: The Latest Minimally Invasive Technologies

Boston Scientific recently partnered with the physician education platform ReachMD, to launch a video and podcast called TAVR Talks: The Latest Minimally Invasive Technologies. The segment provides in-depth physician perspectives on the unique benefits of structural heart technologies available from Boston Scientific, including the newly FDA-approved LOTUS Edge™ Aortic Valve System, ACURATE neo™ Aortic Valve System* and the SENTINEL™ Cerebral Protection System.

As Dr. Michael Reardon notes about the LOTUS Edge valve, a transcatheter aortic valve replacement (TAVR) technology used to treat severe aortic stenosis: “It’s the only valve we have that I can deploy to complete deployment, look at it, decide if I like it, and if I like it, I’ll let it go, and I know what I’m getting. If I don’t like it, I can take it out, move it, change it, do whatever I want.”

Rounding out the piece, we hear about the impact of TAVR with the LOTUS Edge valve through the words of patient Allen Brady and his wife and caregiver, Dianne. Allen, a retired navy captain, purple heart recipient, avid golfer and author of newly published memoir, admits that the thought of open-heart surgery was unnerving. In learning that TAVR provided a significantly less invasive option, he and Dianne became hopeful again. Today, Allen and Dianne agree that the procedure improved his quality of life and may have given them more time to enjoy life together.

“I’ll be 90 next August, and it absolutely makes me feel that way, that I got a payback for [my time spent in the Navy]. I thank the doctors and the scientists and the people that are constantly trying to improve things.”

See Allen’s full story and learn more about some of the latest minimally-invasive structural heart technologies from Boston Scientific here.

Safety information for the LOTUS Edge™ Aortic Valve System is available here.  

* The ACURATE neo™ Aortic Valve System is not available for sale or use in the U.S.

Host Dr. Matt Birholz, introduction from Dr. Ian Meredith, AM, executive vice president and global chief medical officer, Boston Scientific, Clinical experiences shared by Drs. Dean Kereiakes, Michael Reardon, Samir Kapadia, Vinod Thourani and Hemal Gada